Michael Okunewitch

Stock Analyst at Maxim Group

(0)
# 5014
Out of 5,329 analysts
25
Total ratings
10.00%
Success rate
-34.48%
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
RADX Radiopharm Theranost...
Initiates Coverage On: Buy
12
4.11 191.97% 1 May 1, 2025
CMMB Chemomab Therapeutic...
Maintains: Strong Buy
4 7
1.4 400% 2 Feb 20, 2025
MYNZ Mainz Biomed
Initiates Coverage On: Buy
14
2.9 382.76% 1 Feb 14, 2025
LCTX Lineage Cell Therape...
Maintains: Buy
5 3
0.48 525% 1 Jan 10, 2025
CTOR Citius Oncology
Initiates Coverage On: Buy
3
0.95 215.79% 1 Nov 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
4
0.76 426.32% 1 Oct 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
12
1.01 1088.12% 1 Sep 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
15 6
1.56 284.62% 2 Aug 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
3 12
1.22 883.61% 2 Mar 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
2
n/a n/a 1 Dec 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
24
1.36 1664.71% 1 Oct 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.2 400% 1 Sep 21, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
108 18
3.31 443.81% 3 Aug 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
225
0.68 32988.24% 1 Apr 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
17.45 43.27% 1 Dec 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
1.81 231.49% 1 Sep 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
160
7.64 1994.24% 1 Mar 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
120
n/a n/a 1 Feb 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
25
1.52 1544.74% 1 Nov 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
100
0.76 13057.89% 1 Nov 30, 2021